Chattem Company Profile

✉ Email this page to a colleague

CHATTEM has twenty approved drugs.

There are two US patents protecting CHATTEM drugs.

There are sixty-seven patent family members on CHATTEM drugs in forty countries and two supplementary protection certificates in two countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	GAVISCON	aluminum hydroxide; magnesium trisilicate	TABLET, CHEWABLE;ORAL	018685-001	Dec 9, 1983		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Chattem Sanofi	ZANTAC 75	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020745-001	Feb 26, 1998		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-008	Jan 24, 2011		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	SOLUTION;ORAL	209090-001	Jan 31, 2017		OTC	Yes	Yes	8,633,194	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	TABLET;ORAL	020872-005	Jan 24, 2011	6,399,632*PED	⤷ Sign Up
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021909-002	Jan 24, 2011	7,138,524	⤷ Sign Up
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-008	Jan 24, 2011	5,578,610*PED	⤷ Sign Up
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-005	Aug 2, 1996	8,999,379	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Suspension	30 mg/5 mL	➤ Subscribe	2010-01-25
➤ Subscribe	Oral Solution	0.5 mg/mL	➤ Subscribe	2009-01-14
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2007-10-30
➤ Subscribe	Transdermal System	7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs	➤ Subscribe	2014-05-30
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2007-12-17

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Tunisia	SN08186	⤷ Sign Up
Eurasian Patent Organization	200700067	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2006005507	⤷ Sign Up
Argentina	058323	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663828	C300085	Netherlands	⤷ Sign Up	PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146	2001C/045	Belgium	⤷ Sign Up	PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.